Article Text

Download PDFPDF
Esomeprazole did not universally improve asthma outcomes in moderate to severe stable asthma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with moderate to severe stable asthma, does treatment with esomeprazole improve asthma outcomes?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Gastroenterology ★★★★★★☆ Respirology ★★★★★☆☆


Embedded ImageDesign:

randomised, placebo controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {patients, healthcare providers, data collectors, outcome assessors, data analysts, monitoring committee, and manuscript writers}.*

Embedded ImageFollow up period:

16 weeks.

Embedded ImageSetting:

122 centres in North and South America and Europe.

Embedded ImagePatients:

770 patients 18–70 years of age (mean age 45 y, 70% women) with stable, adequately treated asthma, FEV1 50–80% of predicted with ⩾12% reversibility, and mean morning peak expiratory flow (PEF) <80% predicted. Exclusion criteria included recent use of a proton pump inhibitor and recurrent moderate to severe symptoms of gastro-oesophageal reflux disease (GORD) in patients >40 years of age. During …

View Full Text


  • * See glossary.

  • Information provided by author.

  • For correspondence: Dr T Kiljander, Tampere University Hospital, Tampere, Finland. toni.kiljander{at}

  • Source of funding: AstraZeneca.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd